A Department of Defense (DoD)-funded Phase I/II clinical study on TapImmune's HER2/neu-targeted T-cell vaccine for women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS)

Trial Profile

A Department of Defense (DoD)-funded Phase I/II clinical study on TapImmune's HER2/neu-targeted T-cell vaccine for women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs TPIV 110 (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2017 According to a TapImmune media release, the company plans to initiate a Phase 1b/2a clinical trial of TPIV 110 for treating women with HER2/neu+ breast cancer once an amended investigational new drug application (IND) is completed by year-end 2017 and upon FDA acceptance of the amended IND.
    • 17 Mar 2017 New trial record
    • 14 Mar 2017 This study is expected to begin in 2017 and will be led by Keith Knutson, according to a TapImmune media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top